# The Role of Systemic Immuno-inflammatory Factors in Resectable Pancreatic Adenocarcinoma

> **NCT05025371** · — · COMPLETED · sponsor: **Iuliu Hatieganu University of Medicine and Pharmacy** · enrollment: 312 (actual)

## Conditions studied

- Pancreas Cancer, Duct Cell Adenocarcinoma

## Interventions

- **OTHER:** Systemic immune-inflammatory markers

## Key facts

- **NCT ID:** NCT05025371
- **Lead sponsor:** Iuliu Hatieganu University of Medicine and Pharmacy
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2021-08-01
- **Final completion:** 2021-08-01
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2021-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025371, "The Role of Systemic Immuno-inflammatory Factors in Resectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05025371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*